News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arrayit Diagnostics Announces $8 Million Financing Commitment


10/4/2012 7:40:28 AM

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Arrayit Corporation (OTCQB: ARYC) is pleased to announce that Arrayit Diagnostics, Inc. (“AD”) has secured a financing commitment from American Equity Fund, LLC to purchase up to $8 million of the common stock of AD. This financing will commence upon the completion, filing, and approval by the SEC of the S-1 Registration Statement. The specific terms and conditions of the financing commitment will be fully disclosed in the Form S-1.

John Howell, President and CEO of AD, stated, “I am very pleased with the completion of this financing package, as AD now has the necessary financial resources to reach the next critical milestone in the expansion of the research and development of disease states beyond current activities.”

Rene Schena, Arrayit Corporation CEO, adds, “This important milestone illustrates the value of microarray-based testing in oncology and other human disease areas. The capital raise in Arrayit Diagnostics represents an important step in our growth strategy.”

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.

About Arrayit Diagnostics

Arrayit Diagnostics, headquartered in Redmond, Oregon, is leading the research and approval process of diagnostic tests for cancer based on molecular diagnostic technology.

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-KA for the fiscal year ended December 31, 2011 and Form 10-Q for the quarters ended March 31, 2012 and June 30, 2012.

Contact:

For Arrayit Corporation

Steven Scott, 617-448-1300


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES